The Canadian government has authorized a startup to export psychedelic substances to Australia for medical purposes. Optimi Health Corp. has been given the responsibility to ship pills containing psilocybin, an element derived from magic mushrooms, and MDMA, as sanctioned by the health department.
The increasing demand goes beyond locally available magic mushrooms in Ontario. Other countries are following Canada’s lead and are beginning to investigate and allow the use of serotogenic substances for medicinal applications.
Securely buy psychedelics online in Canada and tap into your innate potential through trustworthy sources.
[toc]Main Points:
- Optimi Health, a Vancouver-based startup, has received a drug establishment license to export magic mushroom capsules to Australia.
- Australia allows licensed psychiatrists to use magic mushrooms in treating chronic depression.
- The treatment consists of three sessions over a span of five to eight weeks, with each session lasting around eight hours.
Rise of Psilocybin Capsules in Canada
Optimi, a startup from Vancouver, aims to use its license to broaden the pharmaceutical market for psychedelic substances and gain an edge with early market entry.
Seven firms have exported psilocybin, MDMA, or both, but exclusively for clinical trial reasons. A spokesperson from Canada’s health department was unable to confirm if these exports were for regular patient use and opted not to reveal the firms due to security reasons.
This accomplishment places Optimi among a limited group of global suppliers, with the existing market favoring clinical over recreational use.
What’s in the Pill?
Although the company hasn’t detailed the specific mushroom used in the pill, they do utilize a range of strains, including Albino Penis Envy, among others.
Optimi has established a 20,000-square-foot facility in Princeton, British Columbia, to cultivate, test, and extract its psychedelic mushrooms. The town, with approximately 3,000 inhabitants, is located three hours to the east of Vancouver.
The Connection Between Australia and Psychedelic Mushrooms
It’s estimated that one in every five Australians, aged between 16 and 85, may experience a mental health issue. Post-traumatic stress disorder (PTSD) is likely to impact 11% of Australians in their lifetime, and anxiety disorders are common in 17% of the population.
While numerous methods exist to treat mental health conditions, not all are equally effective for everyone. Individuals who don’t respond to certain treatments can find it difficult to identify a method that works for them, which can exacerbate their vulnerability.
Explaining the Process
Australia has been a leader in using psilocybin, allowing licensed psychiatrists to employ this controlled substance in the treatment of PTSD and treatment-resistant depression.
In a notable decision in February, Australia’s Therapeutic Goods Administration (TGA) reclassified MDMA and psychedelic mushrooms for therapeutic purposes. The TGA indicated that these substances are safe when used in a medically supervised setting for patients with severe mental disorders.
This shift has been revolutionary for many mental health professionals and researchers. The administration of these substances will be meticulously monitored; it’s not as simple as taking a pill and departing.
The treatment regimen typically includes three sessions over a five to eight-week period. Each session lasts roughly eight hours, with the therapist present throughout the entire duration.
Canada’s Role in Psilocybin Research
Canada has become a significant center for psilocybin research, greatly expanding our understanding of this substance. Health Canada, along with various institutions, is spearheading the investigation into the therapeutic possibilities of psilocybin for different mental health disorders.
Research institutions are no longer required to classify these substances as illegal or rely on unauthorized dispensaries or mushroom stores. The government now permits certain institutions to grow mushrooms for research purposes.
The increased accessibility to substances once deemed harmful allows researchers to deepen their understanding of their potential benefits.
A Recurrent Trend
Since the 1950s, the potential of this area has been realized for tackling mental health problems and substance misuse, including alcohol addiction. The pioneering research was led by English psychiatrist Humphry Osmond and Canadian biochemist Abram Hoffer at the Weyburn The Saskatchewan Mental Hospital. The hospital witnessed significant progress under the leadership of then-premier Tommy Douglas, who granted the medical fraternity considerable freedom to investigate their medical theories.
Dr. Osmond and Dr. Hoffer began investigations with LSD, mescaline, and peyote as possible alternatives to the harsh methods of electroshock and lobotomy. Their research took surprising turns, as they encouraged doctors, nurses, and support staff to experiment with these substances.
Canadian Health Research Institutes
Through the Institute of Neurosciences, Mental Health and Addiction, the Canadian Institutes of Health Research is funding three clinical trials to investigate the therapeutic effectiveness and safety of psilocybin-assisted psychotherapy:
| Project Type | Study Focus | Research Institution | Lead Investigator | Project Budget |
| A randomized controlled trial | Psychological distress in end-of-life situations for patients with advanced cancer | University of Toronto | Sarah Hales | $928,643 |
| Mechanisms underlying psilocybin psychotherapy for alcohol use disorder treatment | Alcohol use disorder | University of Calgary | Leah Mayo | $1,000,000 |
| A randomized phase II clinical trial comparing single vs. dual psychedelic doses | Treatment-resistant depression | University of Toronto | Joshua Rosenblat | $1,000,000 |
This funding will enable a more thorough understanding of the benefits of controlled substances. This opportunity is made possible by the Canadian Drugs and Substances Strategy (CDSS), an initiative by the Government of Canada.
Further Psychedelic Research
In Vancouver, psychiatrists have initiated a phase III clinical trial of MDMA, commonly known as ecstasy, for the treatment of post-traumatic stress disorder (PTSD). The treatment includes three eight-hour sessions with MDMA, spaced a month apart, and nine 90-minute sessions without the drug. Researchers regard this trial as historically important, marking the first clinical investigation of an illicit
It’s been over forty years since such a psychedelic substance was studied.
Grasping the Concept of Psilocybin
Psilocybin is a naturally existing psychedelic compound found in certain species of mushrooms. Upon ingestion, it metabolizes into psilocin, which then activates the serotonin 5-HT2a receptors located on the cortical pyramidal cells in the brain – the primary processing sites.
The compound is currently under investigation by local authorities due to its potential in aiding depression, anxiety, addiction, and distress related to end-of-life, by promoting introspection and spiritual enlightenment.
What Makes Psilocybin Potentially Effective Against Depression, PTSD, and Other Conditions?
The active ingredient influences various brain areas, indicating its potential usefulness for different mental disorders. In Canada and Australia, numerous patients have already undergone treatment with this therapy. The reported results are promising, with minor side effects such as temporary anxiety or increased blood pressure.
Effects on Neurobiology
- Activation of Serotonin Receptors: The compound acts as a partial agonist at serotonin receptors, specifically the 5-HT2A subtype, which is vital for emotional processing and mood regulation.
- Manipulation of the Default Mode Network (DMN): The compound reduces activity in the DMN, promoting introspection, decreasing rigid thought patterns, and encouraging emotional adaptability.
- Stimulation of Prefrontal and Limbic Regions: The antidepressant effects of the compound result from its influence on the prefrontal and limbic regions of the brain, including the amygdala. In depression cases, individuals typically show a reduced response to emotional stimuli. This compound enhances the response to positive emotional stimuli in the right amygdala and diminishes or normalizes the response to negative or neutral emotional stimuli.
Psychological and Emotional Effects:
- Promotion of Positive Mood States: The compound triggers feelings of euphoria, interconnectedness, and emotional openness during and after the experience.
- Enhanced Emotional Processing: The psychedelic experience may allow individuals to safely face and process deep-seated emotions, traumatic memories, or existential concerns in a supportive setting.
- Spiritual and Existential Insights: Research from Johns Hopkins University and Imperial College Studies suggest that London’s use of magic mushrooms can lead to long-term positive changes such as improved well-being, enhanced satisfaction in life, and spiritual growth.
What Can Your Local Magic Mushroom Store Offer?
Interested in how this substance may affect your mental health? Explore your local magic mushroom shop to find a product that suits your requirements.
| Product | Quantity | Potency | Benefits |
| Evoke – Medicinal Mushrooms | 20 | 100mg or 200mg | Improves mood, stimulates creativity, and enhances productivity and focus |
| Ground Sounds – Microdose Capsules – Super Freak | 30 | 50mg, 100mg, and 250mg | Promotes better wellness and improves overall quality of life |
| Kind Stranger – Microdose Capsules – Sidekick | 30 | 100mg | Promotes mental clarity, creativity, and focus. Comprises a potent mixture of clinical-strength adaptogenic herbs |
| Osmosis – Brain Boost | 30 | 100mg or 200mg | Provides cognitive and energy benefits |
Psilocybin’s Worldwide Recognition
Canada isn’t the only country advocating for the use of magic mushrooms in treating mental health disorders. Countries like Australia are also recognizing these hallucinogens as potential solutions for conditions such as depression and PTSD. They are procuring high-quality psychedelic capsules from trustworthy sources. Under proper supervision, these substances can immensely improve patients’ quality of life. Micro Zoomiez Canada, a magic mushroom retailer, offers a variety of products, ranging from tablets to LSD edibles.
Frequently Asked Questions
What is the similarity between psilocybin and MDMA?
Both psilocybin and MDMA show therapeutic potential by enhancing mental health. Psilocybin interacts with the serotonin 2A receptors and is effective in treating depression and addiction.
Conversely, MDMA encourages empathy and is beneficial in the treatment of PTSD. It displays potential in improving emotional processing and
Despite being listed as a controlled substance, it has shown promising therapeutic results.
Is this treatment accessible to all Australians?
No, not all Australians are eligible for this treatment. Individuals in Australia must first undergo an evaluation to assess their suitability for using the substance. This assessment takes into account factors such as existing heart problems and a history of psychosis among other things. Only patients who have not responded to conventional treatments for conditions such as depression, anxiety, or PTSD can avail of this treatment.
What are the implications of Canada exporting mushrooms?
Canada is strategically positioning itself to take the lead in the psychedelics market, mirroring its approach with cannabis. This could lead to more companies producing top-tier products. As a result, Canada could become a leading player in the hallucinogen market, strengthen its economy, and make treatments more accessible to other countries. This would also prevent other countries from relying on illegal dispensaries or suppliers for their hallucinogens, thereby ensuring safety.
Articles That May Interest You:
